FeesSafety
Pluang+

Syndax shares drop over 11% after axatilimab fails Phase 2 trial in lung disease IPF

Market News
14 Oct 2026, 05:17 WIB
PRNewsWire
View Source
Bearish
Syndax shares drop over 11% after axatilimab fails Phase 2 trial in lung disease IPF

Syndax Pharmaceuticals' stock fell more than 11% after its drug axatilimab failed to meet the primary endpoint in a Phase 2 trial for idiopathic pulmonary fibrosis (IPF). The trial showed no benefit in lung function decline, leading Syndax to halt further IPF development. Investors who suffered losses in the selloff may be eligible for compensation, as a securities law investigation is underway.

Syndax Pharmaceuticals' recent stock decline is noted alongside Pluang's health sector data for context. For readers following health stocks, here is Pluang's market snapshot as of Oct 14, 2026 06:21 WIB: out of 128 priced health-sector US stocks, 29 rose and 99 fell. Notable movers include JNJ at USD 249.35 with a 1-day change of -5.45% and a typical hold time of 129 days, HRTX at USD 0.39 down 5.32% with a 36-day hold, and TXG at USD 71.80 down 4.51% with a 92-day hold time and 100% buy order activity.

More News

Gilead raises dividend for 11th year, backed by strong cash flow and expanding drug portfolio.

Gilead raises dividend for 11th year, backed by strong cash flow and expanding drug portfolio.

Gilead Sciences increased its dividend by 3.8% for the 11th consecutive year, supported by strong free cash flow of $10.6 billion over nine months and a conservative payout ratio below 30%. The company maintains a dominant position in HIV therapies w...

Company Fundamentals
Bullish
9 minutes ago
Nvidia stock plunges 23% amid CEO resignation and investigations, trading at a record low P/E of 8.

Nvidia stock plunges 23% amid CEO resignation and investigations, trading at a record low P/E of 8.

Nvidia experienced its worst week since 2008, dropping 23% following CEO Jensen Huang's resignation and multiple investigations into chip exports to China. Despite a strong earnings report showing 103% revenue growth and raised guidance, the stock tr...

Market News
Bearish
32 minutes ago
Bloom Energy's revenue soars 138% but stock drops 60%, raising questions on valuation and growth risks.

Bloom Energy's revenue soars 138% but stock drops 60%, raising questions on valuation and growth risks.

Bloom Energy reported a 138% revenue increase to $1.2 billion in Q3 and raised its full-year guidance for the third time, driven by strong demand for its fuel cells in AI data centers. Despite this growth, the stock has fallen about 60% from its peak...

Company Fundamentals
Neutral
46 minutes ago
Johnson & Johnson remains a strong dividend stock but trades at a premium valuation.

Johnson & Johnson remains a strong dividend stock but trades at a premium valuation.

Johnson & Johnson continues to show resilience with a 64-year dividend increase streak and raised full-year revenue and earnings guidance for 2026. Despite its strong business fundamentals and leadership in pharmaceuticals and medical devices, the st...

Company Fundamentals
Bullish
1 hour ago
Elon Musk plans AI data centers in orbit, sparking bipartisan interest post-Democratic win in Texas Senate race.

Elon Musk plans AI data centers in orbit, sparking bipartisan interest post-Democratic win in Texas Senate race.

After Democrat James Talarico won the Texas Senate seat despite Elon Musk's $200 million backing of his opponent, Talarico expressed willingness to collaborate with Musk. This shift comes amid nationwide voter support for limiting AI data centers on ...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App